-
公开(公告)号：EP3009129B1
公开(公告)日：2017-08-09
申请号：EP15193178.9
申请日：2008-05-29
CPC分类号： A61K38/2235 , A61K9/14 , A61K9/20 , A61K9/2013 , A61K9/2027 , A61K9/2846 , A61K9/48 , A61K9/4858 , A61K9/4866 , A61K9/50 , A61K38/23 , A61K38/29
-
公开(公告)号：EP3009129A1
公开(公告)日：2016-04-20
申请号：EP15193178.9
申请日：2008-05-29
CPC分类号： A61K38/2235 , A61K9/14 , A61K9/20 , A61K9/2013 , A61K9/2027 , A61K9/2846 , A61K9/48 , A61K9/4858 , A61K9/4866 , A61K9/50 , A61K38/23 , A61K38/29
摘要： Acid-containing oral pharmaceutical compositions are provided wherein the pharmaceutical active agents are peptide compounds (i.e., those that include a plurality of amino acids and at least one peptide bond in their molecular structures). Certain barrier/layers and/or particulate coated acid are used to reduce any adverse interactions that might otherwise occur between the acid of the compositions and other component of the composition. Use of these barrier layers and/or use of particulate coated acid is believed to promote a more simultaneous release of the components of the composition that is achieved by prior art acid-protection techniques, thus enhancing, and making more consistent, the bioavailability of the active peptide compounds.
摘要翻译： 提供含酸的口服药物组合物，其中药物活性剂是肽化合物（即，包括多个氨基酸和其分子结构中至少一个肽键的那些）。 某些屏障/层和/或颗粒涂覆的酸用于减少组合物的酸和组合物的其它组分之间可能发生的任何不利相互作用。 认为使用这些阻挡层和/或使用颗粒涂覆的酸促进通过现有技术的酸保护技术实现的组合物组分的更多同时释放，从而增强和使一致的生物利用度 活性肽化合物。
-
3.发明授权METHOD FOR ASSISTING IN DIFFERENTIAL DIAGNOSIS AND TREATMENT OF AUTISTIC SYNDROMES 失效法配套的鉴别诊断和治疗自闭症综合征
公开(公告)号：EP1019072B1
公开(公告)日：2005-05-11
申请号：EP98924800.0
申请日：1998-05-19
申请人： REPLIGEN CORPORATION
发明人： HORVATH, Karoly , Beck, Victoria
IPC分类号： A61K38/00 , A61K38/28 , A61K38/16 , A61K39/00 , A61K39/38 , A61K31/495 , A61K31/50 , G01N33/566 , A01N37/18 , A01N43/58 , A01N43/60
CPC分类号： G01N33/6893 , A61K31/045 , A61K31/047 , A61K31/12 , A61K31/121 , A61K31/201 , A61K31/495 , A61K31/575 , A61K36/48 , A61K36/484 , A61K38/2235 , G01N2333/645 , G01N2800/28 , G01N2800/38 , A61K2300/00
摘要： A novel relationship between pancreatico-biliary secretion and autistic syndrome is disclosed. This relationship enables a novel therapy for the treatment of the symptoms of autistic syndromes, comprising the administration of a therapeutically effective, preferably intravenous, dose of secretin to an individual with autistic syndrome. The relationship further enables a differential diagnosis for autistic syndrome, comprising an analysis of an individual's blood and/or intestinal tissue for the presence of secretin and comparison of the level of secretin to known norms.
-
公开(公告)号：EP1461000A2
公开(公告)日：2004-09-29
申请号：EP02804082.2
申请日：2002-11-27
IPC分类号： A61K6/00
CPC分类号： A61K9/1278 , A61K8/0291 , A61K8/14 , A61K8/553 , A61K8/64 , A61K8/86 , A61K9/1075 , A61K9/1271 , A61K38/2013 , A61K38/2235 , A61K38/2278 , A61K38/26 , A61Q19/00 , A61Q19/08
摘要： Provided are methods of treatment of many different diseases and disorders using micelle and sterically stabilized crystalline compounds of the invention.
-
5.发明公开Secretin and agent containing it for the prophylaxy of aspiratory pneumonia syndrome 失效分泌物及其含有ASECRETIN及其代谢物的药物及其代谢物，用于预防肺炎综合征螺旋体PNEUMONIA SYNDROME
公开(公告)号：EP0150760A3
公开(公告)日：1988-06-08
申请号：EP85100363
申请日：1985-01-16
CPC分类号： A61K38/2235
摘要： Die Erfindung betrifft die Verwendung von Sekretin und dieses enthaltende Mittel bei der Prophylaxe des Aspirations- Syndroms.
摘要翻译： 含有促胰液素的药物用于预防吸入性肺炎。
-
公开(公告)号：EP4397678A3
公开(公告)日：2024-09-18
申请号：EP23202326.7
申请日：2018-05-04
IPC分类号： A61K38/00 , A61K38/22 , A61P1/16 , C07K14/575 , C07K14/645 , C07K14/705
CPC分类号： C07K14/645 , A61P1/16 , A61K38/2235
摘要： Disclosed is a method of modulating the Sct/SR axis in a mammalian subject in need thereof, including in a subject suffering from a liver disease, such as but not limited to, Early Stage PBC, Primary Sclerosing Cholangitis, Primary Biliary Cholangitis, Biliary Atresia, NASH, NAFLD, or Alcohol induced liver injury. A method of treating Late Stage PBC in a mammalian subject in need thereof is also disclosed; further disclosed is a method of ameliorating PBC-induced biliary damage in a mammalian subject in need thereof. Pharmaceutical compositions for modulating the Sct/SR axis, comprising a SR antagonist or a SR agonist, and a pharmaceutically acceptable carrier or excipient are also disclosed.
-
7.发明公开PROADRENOMEDULLIN ALONE OR IN COMBINATION WITH BIG GASTRIN I AS A THERAPEUTIC AGENT 审中-公开肾上腺髓质素单独或与大胃泌素我AS的治疗剂组合
公开(公告)号：EP2185179A1
公开(公告)日：2010-05-19
申请号：EP08785862.7
申请日：2008-09-09
发明人： BEVEC, Dorian , CAVALLI, Fabio , CAVALLI, Vera , BACHER, Gerald
IPC分类号： A61K38/22 , A61P31/20 , A61P3/00 , A61P11/00 , A61P9/00 , A61P25/28 , A61P31/06 , A61P35/00 , A61P37/00
CPC分类号： A61K38/2242 , A23L33/18 , A23L33/40 , A23V2002/00 , A61K38/2235 , Y02A50/385 , Y02A50/402 , Y02A50/409 , Y02A50/411 , Y02A50/414 , Y02A50/415 , Y02A50/423 , A61K2300/00 , A23V2200/308 , A23V2200/318 , A23V2200/322 , A23V2200/324 , A23V2200/326 , A23V2250/55
摘要： The present invention is directed to the use of the peptide compound His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 as a therapeutic agent for the prophylaxis and/or treatment of cancer, autoimmune diseases, fibrotic diseases, inflammatory diseases, neurodegenerative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the present invention relates to pharmaceutical compositions preferably in form of a lyophilisate or liquid buffer solution or artificial mother milk formulation or mother milk substitute containing the peptide His-Ser-Asp-Gly-Ile-Phe-Thr-Asp-Ser-Tyr-Ser-Arg-Tyr-Arg-Lys-Gln-Met-Ala-Val-Lys-Lys-Tyr-Leu-Ala-Ala-Val-Leu-Gly-Lys-Arg-Tyr-Lys-Gln-Arg-Val-Lys-Asn-Lys-NH2 optionally together with at least one pharmaceutically acceptable carrier, cryoprotectant, lyoprotectant, excipient and/or diluent.
-
公开(公告)号：EP1461000A4
公开(公告)日：2007-07-25
申请号：EP02804082
申请日：2002-11-27
申请人： UNIV ILLINOIS
发明人： ONYUKSEL HAYAT , RUBINSTEIN ISRAEL
IPC分类号： A61K8/14 , A61K8/55 , A61K8/64 , A61K8/86 , A61K9/107 , A61K9/127 , A61K9/51 , A61K38/22 , A61Q19/00 , A61Q19/08
CPC分类号： A61K9/1278 , A61K8/0291 , A61K8/14 , A61K8/553 , A61K8/64 , A61K8/86 , A61K9/1075 , A61K9/1271 , A61K38/2013 , A61K38/2235 , A61K38/2278 , A61K38/26 , A61Q19/00 , A61Q19/08
摘要： Provided are methods of treatment of many different diseases and disorders using micelle and sterically stabilized crystalline compounds of the invention.
-
公开(公告)号：EP1605960A2
公开(公告)日：2005-12-21
申请号：EP04720417.7
申请日：2004-03-12
申请人： REPLIGEN CORPORATION
IPC分类号： A61K38/00
CPC分类号： A61K38/2235
摘要： The invention is based, in part, on the discovery that secretin and secretin analogs can be used to treat affective disorders that include symptoms of anxiety. Secretin and secretin analogs can be administered to patients to treat affective disorders, such as mood, psychotic, mental, substance-abuse withdrawal, eating, and sexual disorders, as well as other disorders with attendant sensory processing dysfunction, including symptoms of anxiety and/or fear. In addition, secretin and secretin analogs can be administered to improve cognition, including learning and memory, as well as to lessen the effects of conditioned startle. Secretin has the added benefit of causing no negative side effects upon administration and being easy to administer.
-
公开(公告)号：EP1105147A1
公开(公告)日：2001-06-13
申请号：EP99933901.3
申请日：1999-07-12
发明人： MCMICHAEL, John
CPC分类号： A61K38/2235
摘要： Methods are provided of treating the symptoms of neurological disorders including those selected from the group consisting of autism, multiple sclerosis and enuresis by administering to a patient diagnosed with the neurological disorder a composition containing an effective amount of secretin.
-
-
-
-
-
-
-
-
-
搜索结果
51 条记录 (耗时 0.023 秒)
